A research study of how a new medicine called amycretin, given as tablets, works in Japanese men with obesity
Phase 1
- Conditions
- Obesity
- Registration Number
- JPRN-jRCT2071230058
- Lead Sponsor
- Sudoh Yuki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 36
Inclusion Criteria
Male with both parents of Japanese descent
-Body mass index (BMI) between 25.0 and 34.9 kg/m2 (both inclusive). Body weight >=65.0 kg
-Considered eligible based on the medical history, physical examination, and the results of vital
signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening
visit, as judged by the investigator
Exclusion Criteria
-Any disorder that in the opinion from investigators might jeopardise participants safety or
compliance with the protocol
-Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal
disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To investigate the safety and tolerability of NNC0487-0111 after 10 once-daily oral administrations of tablets in Japanese participants with obesity
- Secondary Outcome Measures
Name Time Method To investigate the pharmacokinetic properties of NNC0487-0111 after 10 once-daily oral administrations of tablets in Japanese participants with obesity